We gebruiken cookies om ervoor te zorgen dat onze site zo soepel mogelijk draait. Als je doorgaat met het gebruiken van deze site, gaan we er vanuit dat je ermee instemt.
For image description, please refer to the figure legend and surrounding text.?For the podcast associated with this article, please visit https://academic.oup.com/eurheartj/pages/Podcasts.
This cohort study derives and validates disease-specific, prognostic, quantitative tricuspid regurgitation risk thresholds in transthyretin amyloid cardiomyopathy and compares their prognostic performance with current guideline definitions and the Tricuspid Valve Academic Research Consortium criteria.
Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is increasingly recognized as a common, treatable cause of heart failure, with 5% to 15% of patients thought to have heart failure with preserved ejection fraction diagnosed with amyloid cardiomyopathy. The transformation in the field has been substantial. Improved diagnosis, better heart failure therapy, and disease-modifying therapies are changing the natural history of the disease. Contemporary cohorts demonstrate progressively better survival, with recent data suggesting that outcomes among appropriately treated patients approach those of age-matched individuals. As treatment improves prognosis, identifying the factors that continue to distinguish patients at highest risk becomes increasingly important. The study by Hauptmann and colleagues in JAMA Cardiology adds tricuspid regurgitation (TR) to the expanding list of informative prognostic markers.
This cohort study derives and validates disease-specific, prognostic, quantitative tricuspid regurgitation risk thresholds in transthyretin amyloid cardiomyopathy and compares their prognostic performance with current guideline definitions and the Tricuspid Valve Academic Research Consortium criteria.
Onderwerpen
Blogs
13 dagen geleden
